Cover Image
市場調查報告書

ADME毒性檢驗的全球市場

ADME-Toxicology Testing

出版商 Global Industry Analysts, Inc. 商品編碼 210377
出版日期 內容資訊 英文 291 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
ADME毒性檢驗的全球市場 ADME-Toxicology Testing
出版日期: 2017年05月01日 內容資訊: 英文 291 Pages
簡介

本報告提供全球ADME毒性檢驗市場相關調查,提供您產業概要與市場趨勢,藥物研發的藥物開發趨勢,產品概要,各地區趨勢,企業簡介等彙整資料。

第1章 簡介,調查方法,產品定義

第2章 摘要整理

  • 今後預測
    • 氣勢漸增的ADME毒性實驗
    • ADME毒性檢驗為新藥物研發帶來的影響
    • 現在及未來分析
    • 即使歐美獨佔市場,亞太地區仍有成長氣勢
    • 成長領域in vivo技術產生變化,in vitro技術佔優勢
  • 產業概要
    • 醫藥品產業再度著重成本最佳化
    • 中國與印度:研究開發投資的中心地
    • ADME毒性化驗:概要
    • 早期in vitroADME毒性檢驗的簡介
    • 藥物研發及ADME分析的細胞化驗分析的興起
    • 藥物檢驗的細胞基HTS化驗主要類型
    • CRO的地位擴大
    • 藥物研發的外包和外包服務的種類
    • M&A:潮流
  • 市場趨勢
  • 藥物研發和藥物開發
    • 概要
    • 藥物研發和藥物開發
    • 標的鑑定
    • 標的驗證
    • 領導特定
    • 先導藥物最適化
    • 前臨床檢驗
    • 臨床實驗
    • 藥物研發技術
    • 篩檢的技術創新保證了藥物研發計劃的成功
  • 產品概要
    • ADME毒性:簡介
    • 吸收
    • 分佈
    • 代謝
    • 排泄
    • 毒性
    • ADME毒性分析
    • ADME毒性篩檢技術
    • ADME毒性參數
    • 細胞化驗分析
    • 幹細胞化驗
    • 小腸細胞化驗
    • 腎臟細胞化驗
  • 產品技術創新/引進
  • 近幾年的產業活動
  • 主要企業
    • ACEA Biosciences, Inc.
    • ADMEcell, Inc.
    • Agilent Technologies, Inc.
    • Albany Molecular Research, Inc.
    • Bayer Technology Services GmbH
    • Beckman Coulter, Inc.
    • BioreclamationIVT, LLC
    • Cambridge Cell Networks Ltd.
    • Cerep SA
    • CompuDrug International, Inc.
    • Cyprotex PLC.
    • CeeTox, Inc.
    • Dassault Systemes
    • Entelos, Inc.
    • Elsevier B.V.
    • Eurofins ADME BIOANALYSES SAS
    • Galapagos NV
    • Molecular Discovery Ltd.
    • MultiCASE, Inc.
    • Optivia Biotechnology
    • PerkinElmer, Inc.
    • Pharmaron, Inc.
    • Promega Corporation
    • Qualyst, Inc.
    • Simulations Plus, Inc.
    • Taconic Farms, Inc.
    • Takara Bio Europe AB
    • Tecan Group Ltd.
    • Thermo Fisher Scientific, Inc.
    • Xceleron, Inc.
  • 全球市場預測

第3章 市場

  • 美國
  • 加拿大
  • 日本
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
  • 亞太地區
  • 其他各國

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-7635

This report analyzes the worldwide markets for ADME-Toxicology Testing in US$ by the following Segments: Toxicology Testing (In-Vivo, In-Vitro), and ADME Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 69 companies including many key and niche players such as -

ACEA Biosciences, Inc.
ADMEcell, Inc.
Agilent Technologies, Inc.
Albany Molecular Research, Inc.
Beckman Coulter, Inc.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • ADME-Tox - An Introduction
      • Toxicology Testing
      • ADME Testing

II. EXECUTIVE SUMMARY

1. OUTLOOK

  • ADME-Tox Testing Gains Traction
  • A Peek into the Impact of ADME-Tox Screening on New Drug Discovery
    • Table 1: Phase-I Clinical Trial Failures Before and After the Advent of Preclinical ADME/Pharmacokinetics (includes corresponding Graph/Chart)
    • Table 2: Factors Leading to Failure of Drugs in Phase II Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others (includes corresponding Graph/Chart)
    • Table 3: Factors Leading to Failure of Drugs in Phase III Clinical Trials: Percentage Breakdown of Number of Cases for Efficacy, Pharmacokinetics, Toxicity and Others (includes corresponding Graph/Chart)
    • Table 4: Drug Withdrawals Due to Toxicity Issues (1990-2010): Percentage Share Breakdown of Number of Drugs Withdrawn Due to Cardiotoxicity, Hepatotoxicity and Others (includes corresponding Graph/Chart)
  • Current and Future Analysis
  • US and Europe Dominate, Asia-Pacific Lends Growth Momentum
  • Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge

2. INDUSTRY OVERVIEW

  • Pharma Industry Renews Focus on Cost Optimization
    • Table 5: US R&D Productivity Trends in Pharma Industry (2006- 2015) (includes corresponding Graph/Chart)
  • China and India: Hot Spots for R&D Investment
    • Table 6: World R&D Market by Geographic Region (2015 & 2016): Percentage Breakdown of R&D Spending for Asia, Europe, Middle East & Africa, North America and South America (includes corresponding Graph/Chart)
    • Table 7: World Life Science R&D Spending by Geographic Region (2015 & 2016): Spending in US$ Billion for US and Rest of World (includes corresponding Graph/Chart)
  • ADME-Tox Assays - An Overview
  • Introduction of Early In Vitro ADMET Studies
  • Growing Prominence of Cell-based Assays in Drug Discovery and ADME Analysis
    • Table 8: World Cell-based Assays Market by Segment (2016): Percentage Breakdown of Revenue for Products and Services (includes corresponding Graph/Chart)
    • Table 9: World Cell-based Assays Market by Application (2016): Percentage Breakdown of Revenue for ADME, Basic Research and Drug Discovery (includes corresponding Graph/Chart)
    • Table 10: Global Market for Cell-based Assays (2016): Percentage Breakdown of Value Sales by End-User (includes corresponding Graph/Chart)
  • Major Types of Cell-Based HTS Assays for Drug Screening
  • CROs Expand Presence
  • Drug Discovery Outsourcing and Type of Services Outsourced
  • Changing Face of Drug Discovery Outsourcing Activity
  • M&A - Order of the Day

3. MARKET DYNAMICS

  • Current State of ADME-Tox Testing
  • Need for Better Models: A Major Factor Driving Innovation in the Market
  • Focus Shifts to Innovative Approaches
  • In Silico and In Vitro- the Way to Go
  • In Vitro Testing Systems and Its Relevance in Drug Development
    • Growing Inclination towards In-vitro Assays for Toxicology Studies
  • In Silico ADME-Tox Growing at a Fast Clip
    • Advantages of Using In Silico Approaches
    • Factors Hindering Growth
  • 3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing
  • Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing
  • Rising Number of Drug Targets Surge Demand for Cell-Based Assays
  • Growing Focus on the Development of Reproducible and Robust Cell-based Assays
  • Functional Assays: An Effective Way of Predicting Specific Toxic Effects
  • GPCR Targets to Drive Growth in Functional Cell Assay Market
  • New Alternatives for Early-Stage Toxicology Testing
  • Stem Cells Exude Great Potential in Drug Toxicity Testing
  • Primary Hepatocytes Become Standard Tool for Evaluation in Hepatic Metabolism
  • Improved Cryopreservation Technologies Help Expand Use of Hepatocytes
  • Cardiotoxicity Testing Gains Prominence
  • Cell Imaging-Gaining Popularity
  • In Vivo Imaging Persists in ADME-Tox Testing
  • Computational Models on Rise
  • Adoption of Data Management Systems
  • Drug Transporter Analysis Becoming Part of ADME Assessment
  • Slow Metabolism of Novel Drugs Call for More Human Models in Screening
  • Further Advances Required for More Understanding of Biotransformation
  • Introduction of Third Dimension in Cell Culturing Drives Need for New Instrumentation
  • Regulatory Bodies Focus on Transporter Mediated DDIs

4. DRUG DISCOVERY & DEVELOPMENT

  • Overview
    • Table 11: Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart)
  • Drug Discovery and Development
  • Target identification
  • Target Validation
  • Lead Identification
  • Lead Optimization
    • Pharmaceuticals - R&D Value Chain
  • Pre-Clinical Testing
  • Clinical Trials
    • Clinical Trials - The Time Line
  • Drug Discovery Technologies
  • Innovation in Screening Guarantees Success for Drug Discovery Programs

5. PRODUCT OVERVIEW

  • ADME-Tox - An Introduction
  • Absorption
  • Distribution
  • Metabolism
  • Excretion
  • Toxicity
  • ADME-Tox Profiling
  • ADME-Tox Screening Technologies
  • ADME-Tox Parameters
  • Cell Based Assays
  • Liver Cell Based Assays
  • Intestinal Cell Based Assays
  • Kidney Cell Based Assays

6. PRODUCT INNOVATIONS/INTRODUCTIONS

  • Corning Adds Two New Products to ADME/Tox Lineup
  • Sovicell and 3B Pharmaceuticals Launch EScalate Assay Service
  • Lonza Launches Human and Animal Hepatocytes for Adme-Tox Testing
  • Cyprotex Launches Eight New Transporter Assays
  • Simulations Plus Rolls Out Version 8.0 of ADMET Predictor(tm) Software
  • Simulations Plus Launches Version 7.2 of ADMET Predictor(tm) Software
  • BioReliance(r) Unveils Select In Vitro ADME and Toxicology Testing Services
  • Cyprotex Releases SenCeeTox(r) Technology with Enhanced Capabilities
  • Cyprotex Expands In-House Drug Transporter Services
  • Cyprotex Launches KeratinoSens(tm) Service
  • Simulations Plus Introduces ADMET Predictor Version 7.1
  • Lena Biosciences Launches SeedEZ 3D Cell Culture Products
  • Sigma(r) Life Science to Introduce Genetically-Modified HepaRG(tm) Human Liver Cell Line

7. RECENT INDUSTRY ACTIVITY

  • Simulations Plus to Take Over DILIsym Services
  • Simulations Plus and Electrolab India Sign Distribution Deal
  • Simulations Plus Inks Distribution Deal with Quantum Bio Solutions for Korean Market
  • Cyprotex Moves to New Location in the UK
  • Pharmaron Takes Over Xceleron
  • Evotec Acquires Cyprotex
  • Endonovo Expands Cytotronics Platform for Toxicology Testing
  • Takara Bio Acquires Cellectis AB
  • WuXi PharmaTech Acquires XenoBiotic Laboratories
  • Merck KGaA to Take Over Sigma-Aldrich
  • Dassault Systemes Acquires Accelrys
  • Organovo Collaborates with J&J for 3D Bioprinting Drug Discovery Research
  • Taconic and IVAL Enter into Agreement
  • Charles River to Acquire Galapagos' Argenta and BioFocus Service Divisions
  • Simulations Plus Signs 5-Year RCA with the US FDA
  • Simulation Plus Inks Distributor Agreement with RILD
  • Harlan CRS Enters into Strategic Alliance with Bertin Pharma
  • Pharmaron Receives GLP Certification from the CFDA for GLP Toxicology Facilities
  • Cyprotex Acquires CeeTox
  • Taconic Announces Name Change
  • Rosa & Co. Acquires Entelos Holdings' Consulting Service Business
  • Thermo Fisher Scientific Acquires Life Technologies

8. FOCUS ON SELECT PLAYERS

  • ACEA Biosciences, Inc. (USA)
  • ADMEcell, Inc. (USA)
  • Agilent Technologies, Inc. (USA)
  • Albany Molecular Research, Inc. (USA)
  • Beckman Coulter, Inc. (USA)
  • BioreclamationIVT, LLC (USA)
  • Cerep SA (France)
  • CompuDrug International, Inc. (USA)
  • Cyprotex PLC. (UK)
  • CeeTox, Inc. (USA)
  • Dassault Systemes Biovia Corp. (USA)
  • Eurofins ADME BIOANALYSES SAS (France)
  • Galapagos NV (Belgium)
  • Molecular Discovery Ltd. (UK)
  • MultiCASE, Inc. (USA)
  • Optivia Biotechnology (USA)
  • PerkinElmer, Inc. (USA)
  • Pharmaron, Inc. (USA)
  • Promega Corporation (USA)
  • Qualyst, Inc. (USA)
  • Simulations Plus, Inc. (USA)
  • Taconic Biosciences, Inc. (USA)
  • Takara Bio Europe AB (Sweden)
  • Tecan Group Ltd. (Switzerland)
  • Thermo Fisher Scientific, Inc. (USA)

9. GLOBAL MARKET PERSPECTIVE

    • Table 12: World Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 13: World Historic Review for ADME-Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 14: World 14-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 15: World Recent Past, Current & Future Analysis for Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 16: World Historic Review for Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 17: World 14-Year Perspective for Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 18: World Recent Past, Current & Future Analysis for Toxicology Testing by Segment - In-Vivo and In-Vitro Toxicology Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 19: World Historic Review for Toxicology Testing by Segment - In-Vivo and In-Vitro Toxicology Testing Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 20: World 14-Year Perspective for Toxicology Testing by Segment - Percentage Breakdown of Revenues for In-Vivo and In-Vitro Toxicology Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 21: World Recent Past, Current & Future Analysis for In-Vivo Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 22: World Historic Review for In-Vivo Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 23: World 14-Year Perspective for In-Vivo Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 24: World Recent Past, Current & Future Analysis for In-Vitro Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 25: World Historic Review for In-Vitro Toxicology Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 26: World 14-Year Perspective for In-Vitro Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 27: World Recent Past, Current & Future Analysis for ADME Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 28: World Historic Review for ADME Testing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 29: World 14-Year Perspective for ADME Testing by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Current & Future Analysis
    • Clinical Trials Market in the US
    • Key Statistics
    • Table 30: Leading Toxicology Testing Laboratories in the US (2016): Percentage Breakdown of Revenue for Alere Toxicology, Medytox Solutions, Quest Diagnostics and Others (includes corresponding Graph/Chart)
    • Product/Service Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 31: US Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 32: US Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 33: US 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

2. CANADA

  • Market Analysis
    • Table 34: Canadian Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 35: Canadian Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 36: Canadian 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

3. JAPAN

  • Market Analysis
    • Table 37: Japanese Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 38: Japanese Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 39: Japanese 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Clinical Trials Market in Europe
  • B. Market Analytics
    • Table 40: European Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 41: European Historic Review for ADME-Toxicology Testing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 42: European 14-Year Perspective for ADME-Toxicology Testing by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK, Spain and Rest of Europe Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)
    • Table 43: European Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 44: European Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 45: European 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Current & Future Scenario
    • Key Players
  • B. Market Analytics
    • Table 46: French Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 47: French Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 48: French 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Current & Future Analysis
    • Product Launch
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 49: German Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 50: German Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 51: German 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 52: Italian Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 53: Italian Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 54: Italian 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Current & Future Analysis
    • Product/Service Launches
    • Strategic Corporate Developments
    • Key Players
  • B. Market Analytics
    • Table 55: UK Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 56: UK Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 57: UK 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Current & Future Analysis
    • Garnering Investments from Multinational Pharma Companies
    • Table 58: Apportion of R & D Expenditure by Study Phase in Spain: 2015 (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 59: Spanish Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 60: Spanish Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 61: Spanish 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

4f. REST OF EUROPE

  • A. Market Analysis
    • Current & Future Analysis
    • Clinical Trials Market in Select Regions
      • Russia
    • Table 62: Russian Clinical Trials Market by Trial Type (2015): Percentage Breakdown of Number of Trials for Bioequivalence Studies (Foreign Sponsors), Bioequivalence Studies (Local Sponsors), Global Multi-Center Clinical Trials, Local Clinical Trials (Foreign Sponsors), and Local Clinical Trials (Local Sponsors) (includes corresponding Graph/Chart)
    • Table 63: Russian Clinical Trials Market Volume (2015): Percentage Breakdown of Trials by Hosting Country (includes corresponding Graph/Chart)
    • Product Launch
    • Strategic Corporate Development
    • Key Players
  • B. Market Analytics
    • Table 64: Rest of Europe Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 65: Rest of Europe Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 66: Rest of Europe 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Current & Future Analysis
    • Asia: The Most Preferred Destination for Clinical Trials
    • An Overview of Clinical Trials Market in Select Countries in The Region
      • China
      • Pharmaceutical Outsourcing Sector in China- An Overview
      • Implementation of GLP Standard Makes Data Internationally Acceptable
      • Use of Non-Human Primates- A Key Feature of Chinese Pharmaceutical Sector
      • Going Ahead....
      • India
      • A Thriving Clinical Trials Market
    • Table 67: Cost of Conducting Clinical Trials: India Vs. US (In US$ Thousand) (includes corresponding Graph/Chart)
      • Australia
      • Australia Makes Strong Pitch for Clinical Trials
      • Major Challenges Facing Australian Clinical Trials Market
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 68: Asia-Pacific Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 69: Asia-Pacific Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 70: Asia-Pacific 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Current & Future Analysis
    • Latin America: An Emerging Market for Clinical Trials
    • The Middle East - Brimming with Potential for Clinical Trials
    • Table 71: The Middle East Clinical Trial Market (2015): Percentage Breakdown of Registered Clinical Trials in Iran, Israel, Turkey and Rest of Middle East (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 72: Rest of World Recent Past, Current & Future Analysis for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 73: Rest of World Historic Review for ADME-Toxicology Testing by Segment - Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets Independently Analyzed with Annual Revenues in US$ Thousand for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 74: Rest of World 14-Year Perspective for ADME-Toxicology Testing by Segment - Percentage Breakdown of Revenues for Toxicology (In-Vivo and In-Vitro) and ADME Testing Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE

Back to Top